The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries

Ayhan, Ali̇; Güvenal, Tevfik; Salman, Mehmet Çoşkun; Özyüncü, Özgür; Sakıncı, Mehmet; Başaran, Mustafa

doi:10.1016/j.ygyno.2005.05.028

Cited by 127 publications

(175 citation statements)

References 19 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…In our series, the median survival time was higher for colorectal cancer patients than for gastric cancer patients and this result is consistent with the findings previously reported [6,7]. In this study, gastric cancer accounted for the majority of Krukenberg tumors (73.5%) and there was no survival difference between Krukenberg and non-Krukenberg tumor of gastric origin.…”

Section: Discussionsupporting

confidence: 93%

“…Although the overall survival rates are poor, survival rates vary depending on the primary origin of the tumor [7]. In our series, the median survival time was higher for colorectal cancer patients than for gastric cancer patients and this result is consistent with the findings previously reported [6,7].…”

Section: Discussionsupporting

confidence: 92%

“…This reflects the difficulty in differential diagnosis between primary ovarian neoplasm and metastatic tumors to the ovaries. This problem of differentiating primary ovarian neoplasms from metastastic disease has been confirmed by other investigators [6,7].…”

Section: Discussionsupporting

confidence: 52%

“…The diagnosis of non-genital ovarian metastasis generally has a poor prognosis. The 5-year survival has been reported to be from 10% to 36%; worse than the 40% generally reported for primary ovarian cancer [4,7,8]. Survival is better for patients with metastatic tumors to the ovary from genital rather than non-genital origin [1,3].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries

Kim

et al. 2010

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 52%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries

Kim

et al. 2010

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

“…Colorectal cancer accounts one third of nongenital tumors metastatic to ovaries. [1][2][3][4] Among the patients with peritoneal carcinomatosis (PC) of epithelial ovarian cancer origin, cytoreductive surgery is the standard of care. An attempt at maximal removal of tumor burden yields better survival rates in ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

Cytoreductive Surgery for Intestinal Cancer Patients Metastatic to Ovaries Presenting as Primary Ovarian Cancer

Arık¹

2016

UHOD

View full text Add to dashboard Cite

Colorectal cancer accounts for one third of non-genital tumors metastasize to the ovaries. We aimed to investigate the role of cytoreductive surgery in colon and small intestinal cancer patients with adnexal metastases, which were operated as primary epithelial ovarian cancer. This analysis included 26 patients with adnexal metastasis from colon and distal ileum, patients presented as primary ovarian cancer cases and were operated upon in Zekai Tahir Burak Women's Health Hospital, Gynecologic Oncology Unit between 2008 and 2014. Patients with history of intestinal cancers were not included in the study. The median age of patients was 54 (range= 26-77). Among all patients, 63% were premenopausal and 37% were postmenopausal. Most common presenting symptom was abdominal distention (80%). Optimal cytoreduction was performed in 21 patients. Right hemicolon was the primary site of tumor in 8 patients, while recto-sigmoid and appendiceal tumors were present in 7 and 7 patients, respectively. Isolated ovarian metastases were found in 6 patients, the remaining 20 patients had peritoneal carcinomatosis. Median follow-up was 25 months (ranging 3-59). In total, 11 patients died, of them, two patients had isolated ovarian metastasis, while the remaining nine patients had peritoneal carcinomatosis. Estimated median overall survival was 36.8 months (95% CI= 28.6-45.1 months). Median overall survival of patients who underwent cytoreductive surgery was not reached (36.8+ months), compared with 18.3 (95% CI= 0.0-46.4) months for patients with suboptimal cytoreductive surgery (p= 0.008). This retrospective study showed that cytoreductive surgery might have beneficial effect in selected patients with intestinal cancer metastatic to the adnexal.

show abstract

Nonepithelial Ovarian Malignancies

Berek

Friedlander

Bast

2017

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Compared with epithelial ovarian cancers, nonepithelial ovarian tumors are uncommon, constituting <10% of all ovarian malignancies. They include germ cell malignancies, sex‐cord–stromal tumors, carcinomas metastatic to the ovary, and a variety of extremely rare ovarian cancers, including sarcomas and lipoid cell tumors. Although there are many similarities in the presentation, evaluation, and management of patients, these tumors also have unique features that require special approaches to management. Germ cell malignancies are derived from primordial germ cells of the ovary and can be distinguished by histotype and expression of the biomarkers alpha‐fetoprotein (AFP) and/or human chorionic gonadotropin (hCG). They include dysgerminomas (AFP−hCG−), embryonal carcinomas (AFP+hCG+), immature teratomas (AFP−hCG−), endodermal sinus (yolk sac) tumors (AFP+hCG−), and ovarian choriocarcinomas (AFP−hCG+). Germ cell tumors occur in premenarchal girls and young women, grow rapidly, and can present with a symptomatic pelvic mass. As preservation of fertility is often an important priority, unilateral salpingo‐oophorectomy can often be performed followed by adjuvant platinum‐based therapy. Among the germ cell tumors, dysgerminomas can be bilateral in 10–15% of cases and are associated with gonadal dysgenesis in 5% of cases. Metastatic germ cell cancers can be quite sensitive to chemotherapy and the long‐term survival rate is high, even in advanced stages. At some institutions, young patients with stage IA germ cell tumors are followed carefully after resection and chemotherapy given only if there is recurrence with excellent outcomes. Sex‐Cord‐Stromal tumors include Granulosa‐Stromal tumors, Juvenile Granulosa tumors, and Sertoli–Leydig cell tumors. Granulosa‐Stromal tumors can occur at all ages and produce estrogen resulting in pseudoprecocious puberty in a small fraction of girls, amenorrhea in pre‐menopausal women, and endometrial hyperplasia in postmenopausal adults. Granulosa‐Stromal tumors are indolent and often confined to one ovary where surgery can cure stage I disease in more than 75% of cases. Adjuvant chemotherapy is generally not given after complete resection. Late recurrence has, however, been observed. Persistent or recurrent disease has responded to platinum based and hormonal therapy, including progestational agents, luteinizing hormone‐releasing hormone agonists, and aromatase inhibitors. Inhibin B has been a useful biomarker. Sertoli–Leydig cell tumors generally present in the third or fourth decade, produce androgens, and induce virilization in more than 70% of patients. As many Sertoli–Leydig cell tumors are in early stage and rarely bilateral, unilateral salpingo‐oophorectomy is often performed with 70–90% 5‐year survival.

show abstract

The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries

Cited by 127 publications

References 19 publications

The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries

The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries

Cytoreductive Surgery for Intestinal Cancer Patients Metastatic to Ovaries Presenting as Primary Ovarian Cancer

Nonepithelial Ovarian Malignancies

Contact Info

Product

Resources

About